In just a few days, Gilead Sciences Inc. is expected to reveal data from the first of its two large Phase III studies of remdesivir, a drug which is carrying a huge burden of hope and expectation for its potential in treating COVID-19.
There is some hope that the anti-viral drug could help patients hospitalized with moderate and severe conditions, helping them to...







